Search results
Results From The WOW.Com Content Network
Monoamine oxidase inhibitor. Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are best known as effective antidepressants, especially for treatment-resistant depression and atypical depression. [1]
[35] [29] However, the pathophysiology of Parkinson's disease is complex and multifacted, and MAO-B inhibitors may only slow the progression of the disease and do not halt it. [35] [29] The MAO-B inhibition by oral selegiline shows dosage dependence at typical therapeutic doses and below (i.e., ≤10 mg/day).
Levoamphetamine, similarly to dextroamphetamine, acts as a reuptake inhibitor and releasing agent of norepinephrine and dopamine in vitro. [10][14] However, there are differences in potency between the two compounds. [10][14] Levoamphetamine is either similar in potency or somewhat more potent in inducing the release of norepinephrine than ...
Adderall. Adderall and Mydayis[10] are trade names [note 2] for a combination drug containing four salts of amphetamine. The mixture is composed of equal parts racemic amphetamine and dextroamphetamine, which produces a (3:1) ratio between dextroamphetamine and levoamphetamine, the two enantiomers of amphetamine. [12]
Two common trade brands for ADHD medication, Adderall and Concerta are made from different drug formulas. Adderall is made from amphetamine mixed salts and Concerta is made from methylphenidate.
A few years after the discovery that selegiline was a selective MAO-B inhibitor, two Parkinson's disease researchers based in Vienna, Peter Riederer and Walther Birkmayer, realized that selegiline could be useful in Parkinson's disease. One of their colleagues, Moussa B. H. Youdim, visited Knoll in Budapest and took selegiline from him to ...
Even for people taking Adderall or other prescription amphetamines, the risk is rare. Past research showed psychosis and mania occurred in fewer than 1% of the patients taking prescription ...
Treatment in the initial state aims to attain an optimal tradeoff between good management of symptoms and side effects resulting from enhancement of dopaminergic function. The start of L-DOPA treatment may be delayed by using other medications such as MAO-B inhibitors and dopamine agonists, in the hope of delaying the onset of dyskinesias. [3]